GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) will showcase cardiology innovations at ACC.26, including the newly U.S. FDA 510(k) cleared Photonova Spectra photon‑counting CT, ReadyFix fleet management for MAC VU360 ECG workstations, a U.S. collaboration with Gentuity, and recent Allia Moveo regulatory clearances.
Highlights emphasize ultra‑high‑definition imaging, AI‑enabled workflows, intravascular visualization, and operational tools intended to improve diagnostic confidence and device uptime across the cardiac care pathway.
GE HealthCare (Nasdaq: GEHC) received U.S. FDA 510(k) clearance for Photonova Spectra, a photon-counting CT system featuring Deep Silicon detectors with 8-bin energy resolution, 0.23s rotation speed, NVIDIA-accelerated reconstruction and a one-scan universal workflow. GE expects its innovation investments to support 1–2% revenue growth.
GE HealthCare (NYSE:GEHC) completed the acquisition of Intelerad for a base purchase price of $2.3 billion in cash, creating a cloud-first, AI-enabled enterprise imaging platform across ambulatory, teleradiology, and hospital settings. Intelerad’s first-year revenue is estimated at $270 million with ~90% recurring revenue and Adjusted EBITDA margin >30%. GE HealthCare expects immediate accretion to top-line growth and EBIT margin, slight short-term dilution to Adjusted EPS inclusive of financing costs, and a high-single-digit ROIC by year five.
GE HealthCare (Nasdaq: GEHC) appointed Kevin A. Lobo, Chair and CEO of Stryker (NYSE: SYK), to its Board of Directors effective March 13, 2026.
Mr. Lobo brings more than 25 years of medtech, operational and financial leadership, including service as Stryker CEO since October 2012 and Stryker board chair since July 2014, and experience at Johnson & Johnson, KPMG, Unilever and Kraft Canada.
GE HealthCare (NYSE:GEHC) announced on March 9, 2026 that View, the diagnostic viewer in the Genesis Radiology Workspace, received U.S. FDA 510(k) clearance. View is a cloud‑native, zero‑footprint diagnostic viewer offering high‑performance 2D/3D visualization, AI‑enabled tools, and direct access to Advanced Visualization in a single workflow.
The product aims to reduce radiologist non‑interpretive time (studies cite up to 44%) and enable remote, secure diagnostic access; availability varies by region.
GE HealthCare (Nasdaq: GEHC) will showcase AI, cloud-first and software solutions at HIMSS Global Health Conference & Exhibition 2026 in Las Vegas, March 9-12, 2026. The company will highlight CareIntellect for Perinatal, Command Center, Genesis Radiology Workspace, Imaging 360, Verisound ultrasound solutions, ViewPoint, and Vscan Air enterprise tools.
GE HealthCare emphasizes AI-enabled clinical workflows, device data interoperability through HL7 Caliper FHIR Accelerator membership, and demonstrations on reducing operational complexity for clinicians.
GE HealthCare (Nasdaq: GEHC) announced FDA 510(k) clearances (Feb 19, 2026) for three next‑generation MR innovations: SIGNA Sprint with Freelium (1.5T sealed, helium‑free), SIGNA Bolt (advanced 3T), and SIGNA One (AI workflow ecosystem).
Key benefits claimed include 1% helium use5‑hour ride‑through, ~30% lower gradient power, up to 65% peak power reduction, up to 34% smaller equipment room, and AI workflow automation to improve throughput and consistency.
GE HealthCare (Nasdaq: GEHC) announced an approximately $35 million expansion to its BARDA cost-share contract to accelerate development of AI-powered point-of-care ultrasound for trauma assessment and mass-casualty preparedness. The agreement builds on an October 2023 program and funds automated AI tools, lung and intra-abdominal assessment features, ruggedized field devices, and clinician evaluation activities to generate clinical evidence.
The expansion is majority-funded by BARDA and includes federal contract number 75A50123C00035.
GE HealthCare (Nasdaq: GEHC) declared a cash dividend of $0.035 per share for the first quarter of 2026. The dividend is payable on May 15, 2026 to shareholders of record as of April 3, 2026.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at two upcoming investor conferences: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day on Feb 26, 2026 at 9:30 AM ET and Barclays 28th Annual Global Healthcare Conference on Mar 10, 2026 at 8:00 AM ET.
Webcasts for both events will be available on the company’s investor website on the dates and times listed.